Navigation Links
Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference
Date:5/22/2013

PHILADELPHIA and REHOVOT, Israel, May 22, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Kenneth A. Berlin , President and Chief Executive Officer of Rosetta Genomics, will deliver a corporate update at the Jefferies 2013 Healthcare Conference taking place from June 3-6, 2013 in New York City.  Mr. Berlin's presentation will take place on Tuesday, June 4th at 2:00 p.m. Eastern time.

The presentation will be webcast live and archived online at the Investors section of the Company's website at www.rosettagenomics.com

About Rosetta Cancer Testing Services (formerly the miRview® product line)
Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to asbestos exposure.  The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.  Rosetta's assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment.  In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test™, 60,000 from the Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer Test™ and 226,000 patients from the Rosetta Lung Cancer Test™. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.rosettagenomics.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics.  Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.  Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's development or commercialization of molecular diagnostics, the market acceptance of Rosetta's cancer testing services, particularly the Rosetta Cancer Origin Test™, Rosetta's capitalization of its microRNA platform, Rosetta's patent position and Rosetta's development of personalized medicine products and services constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact:  
Rosetta Genomics 
Ken Berlin , President & CEO
(215) 382-9000, ext. 326
investors@rosettagenomics.com

Investor Contacts:
LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com 
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com


'/>"/>
SOURCE Rosetta Genomics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
2. Rosetta Genomics Announces Exercise and Closing of Underwriters Over-Allotment Option
3. Rosetta Genomics Receives Two Key U.S. Patent Allowances
4. Rosetta Genomics Receives Full Settlement Payment from Sanra Laboratories
5. Empire Genomics Chooses Funakoshi as Japan Distributor
6. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
7. Gentris Corporation Launches New Pharmacogenomics Services
8. Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies
9. Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
10. Elsevier Launches New Open Access Journal: Applied and Translational Genomics
11. AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... OSWEGO, Ore. , Dec. 5, 2016   ... the BioInsight clinical study. The study evaluates the safety ... insertion procedure in an office setting. BioMonitor ... ® technology that is placed underneath a patient,s ... fibrillation and syncope (fainting). Atrial fibrillation is a leading ...
(Date:12/5/2016)... --  TrainerMD , the first HIPAA compliant software collaboration platform for ... Styku . Styku, a California -based ... users world-class, real-time 3D body scanning and analysis. Together with its ... hear and feel their health like never before. ... , , ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) ... 125 for their industry leading training methods that engage their associates and link ... the global elite in employer-sponsored training and development programs. , “The 2017 Training ...
(Date:12/5/2016)... (PRWEB) , ... December 06, 2016 , ... For many ... Lithuanian poetry , both thick and thin. The beauty of the Lithuanian language ... Trafford Publishing). , In this poetry book, Zubinas lyrically explores all aspects of a ...
(Date:12/5/2016)... ... 2016 , ... “Epilepsy Awareness,” which can be found at ... conversation about epilepsy, bearing down on the social stigma and lack of public ... epilepsy within their lifetime. With such a large percentage of people affected, it’s ...
(Date:12/5/2016)... ... ... BSI and Brenntag Canada have been appointed by Chr. Hansen as their ... fruits and beverage colorants effective November 1, 2016. , “The ... product portfolio,” said Steve Brauer, President of Brenntag Specialties, Inc. “Representing Chr. Hansen will ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ("GPP") portfolio company, today announced it has acquired the assets of Frankfurt, ... previously a subsidiary of Chiltern International and focuses on clinical trial drug ...
Breaking Medicine News(10 mins):